OncLive TV

OncLive® TV is an editorial video program featuring one-on-one live and/or virtual interviews with key opinion leaders in the oncology field for their expert insight on breaking news, regulatory updates, practice-changing data presented at medical meetings, and other pivotal topics in a cancer specialty, including breast cancer, lung cancer, genitourinary cancers, gastrointestinal cancers, gynecologic cancers, and hematologic cancers.

Dr. Vail Discusses Emerging Advances in Biomarker Testing in Lung Cancer

May 19th 2022

Eric Vail, MD, discusses emerging advances in biomarker testing in lung cancer.

Dr. Massarelli Discusses Frontline Immunotherapy in NSCLC

May 19th 2022

Erminia Massarelli, MD, PhD, MS, discusses advances in front-line immunotherapy in non–small cell lung cancer.

Dr. Harari on Upright Proton Radiation Therapy in Cancer Care

May 19th 2022

Paul M. Harari, MD, discusses the new upright delivery method of proton radiation therapy in cancer care.

Dr. LoRusso on the Importance of Clinical Trials in MDM2-Amplified Dedifferentiated Liposarcoma

May 19th 2022

Patricia LoRusso, DO, discusses the importance clinical trial enrollment for patients with MDM2-amplified dedifferentiated liposarcoma.

Dr. Blay on the Current Treatment Challenges in Soft Tissue Sarcomas

May 19th 2022

Jean-Yves Blay, MD, discusses current treatment challenges in soft tissue sarcomas.

Dr. Oberstein on Remaining Challenges in Metastatic CRC

May 17th 2022

Paul E. Oberstein, MD, discusses remaining challenges in metastatic colorectal cancer.

Dr. Grivas on the Future of the TROPHY U-01 Regimen in Urothelial Cancer

May 17th 2022

Petros Grivas, MD, PhD, discusses the future of the phase 2 TROPHY U-01 trial regimen in metastatic urothelial cancer.

Dr. Ornstein on Unmet Needs in Refractory RCC

May 17th 2022

Moshe Ornstein, MD, MA, discusses unmet needs in metastatic renal cell carcinoma.

Dr. Oberstein on the CheckMate 9X8 Trial in Metastatic CRC

May 17th 2022

Paul E. Oberstein, MD, discusses the phase 2/3 CheckMate 9X8 trial in metastatic colorectal cancer.

Dr. Fleming on the KEYNOTE-426 Trial in Metastatic RCC

May 17th 2022

Mark T. Fleming, MD, discusses the phase 3 KEYNOTE-426 trial in advanced or metastatic renal cell carcinoma.

Dr. Ghali on Nectin-4 and TROP-2 Expression in Urothelial, Variant Histology Bladder Cancer

May 16th 2022

Fady Ghali, MD, discusses the expression of Nectin-4 and TROP-2 in variant histology bladder cancer and urothelial cancer.

Dr. Nguyen on the Efficacy of IS-002 for Robotic Prostatectomy in Prostate Cancer

May 16th 2022

Hao G. Nguyen MD, PhD, discusses the efficacy and safety of IS-002, a prostate-specific membrane antigen–targeting fluorophore, for image-guided surgery in patients with prostate cancer undergoing robotic prostatectomy.

Inside the Clinic: Experts Explore Case Studies in DLBCL

May 16th 2022

Maher Albitar, MD, and Andre H. Goy, MD, discuss case studies in diffuse large B-cell lymphoma.

Dr. Mitra on Nadofaragene Firadenovec Plus Anti–PD-1 Therapy in BCG-Unresponsive NMIBC

May 16th 2022

Anirban P. Mitra, MD, PhD, discusses data from an assessment of PD-1 and PD-L1 status on transurethral resection specimens collected from patients with non–muscle-invasive bladder cancer who received nadofaragene firadenovec as part of a phase 3 trial.

Dr. Spiess on Key Updates in the Management of Penile Cancer

May 15th 2022

Philippe E. Spiess, MD, MS, FACS, shares key updates in the management of patients with penile cancer.

Dr. Galsky on Updated CheckMate 274 Data With Adjuvant Nivolumab in Urothelial Carcinoma

May 15th 2022

Matthew Galsky, MD, discusses long-term data from the phase 3 CheckMate 274 trial evaluating adjuvant nivolumab vs placebo in patients with high-risk, muscle-invasive urothelial cancer.

Dr. Markowski on the Efficacy of Sabizabulin in Prostate Cancer

May 14th 2022

Mark C. Markowski, MD, PhD, discusses the safety and efficacy of sabizabulin in a phase 1b/2 trial in metastatic castration-resistant prostate cancer.

Dr. Khetrapal on Intracorporeal Robotic vs Open Cystectomy in MIBC

May 14th 2022

Pramit Khetrapal, MD, discusses the results of evaluating intracorporeal robotic vs open cystectomy in a multicenter, randomized trial in patients with muscle-invasive bladder cancer.

Dr. Fleming on the Rationale of the SPOTLIGHT Trial in Prostate Cancer

May 13th 2022

Mark T. Fleming, MD, discusses the rationale and results from the phase 3 SPOTLIGHT trial in prostate cancer.

Inside the Clinic: Experts Discuss Testing for Molecular Abnormalities in AML

May 13th 2022

Maher Albitar, MD, and Andre H. Goy, MD, discuss the importance of testing for molecular abnormalities in acute myeloid leukemia.